Royalty Pharma PLC (NAS:RPRX)
$ 26.66 0.06 (0.23%) Market Cap: 11.85 Bil Enterprise Value: 17.69 Bil PE Ratio: 10.45 PB Ratio: 1.73 GF Score: 81/100

Royalty Pharma PLC at Citi BioPharma Conference Transcript

Sep 08, 2022 / 03:20PM GMT
Release Date Price: $42.99 (+0.66%)
Andrew Simon Baum
Citigroup Inc., Research Division - Global Head of Healthcare Research and MD

I would like to introduce our next session from Royalty Pharma. We have an old friend from Citi, my former counterpart, Chris Hite. And I have an old friend from my Morgan Stanley days, Marshall Urist, so Vice Chairman, and separately, Head of R&D. So thank you both. I don't know whether you want to give a few words in terms of update.

I mean, you're busy prosecuting your business, expanding the capital you have, allocating it, the common refrain that we get when we speak to investors. And frankly, it's not as often as it should be because it doesn't get the attention that it warrants, is great company, lousy stock. So anyway, I thought that was an interesting way to start the conversation. So Chris, over to you and just maybe give us an update.

Christopher Hite
Royalty Pharma plc - Vice Chairman & Executive VP

Well, thank you for having us, and good to see you. I kind of -- I think I like our stock. We had a very successful Analyst Day in May,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot